They have up to 28 days of screening of patients b4 beginning trial so who knows when we'll get dosing completed announcement on SCM.
SCM and Acromegaly can easily get us to a $100M market cap. Let MS work itself out. If it works out, great. If not, its not a company killer. Besides, time wise, MS will be absolutely dead last out of our three main drugs to get to market.
